Q2 2024 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2024-08-09 · accession 0001104659-24-087431
$949.6M
Reported value
15
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $283.0M | 29.8% | 8,020,136 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $159.7M | 16.8% | 5,350,422 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $141.8M | 14.9% | 10,907,859 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $113.1M | 11.9% | 2,509,456 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $88.6M | 9.33% | 6,430,257 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $38.5M | 4.06% | 1,137,149 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $37.6M | 3.95% | 2,092,106 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $23.3M | 2.46% | 8,279,484 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $23.3M | 2.46% | 5,836,874 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $18.9M | 1.99% | 2,098,300 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $8.3M | 0.87% | 5,018,178 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutics, Inc. | $6.2M | 0.66% | 378,447 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $3.5M | 0.37% | 136,979 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $3.0M | 0.31% | 1,799,232 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $695,937 | 0.07% | 535,336 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.